Molecular Partners Ag (MOLN) Cash & Equivalents (2020 - 2025)

Molecular Partners Ag (MOLN) has disclosed Cash & Equivalents for 6 consecutive years, with $103.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 41.83% to $103.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $103.4 million through Dec 2025, up 41.83% year-over-year, with the annual reading at $99.7 million for FY2025, 37.3% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $103.4 million at Molecular Partners Ag, up from $72.9 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $103.4 million in Q4 2025, with the low at $72.9 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $84.3 million, with a median of $77.9 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents tumbled 47.35% in 2021, then skyrocketed 41.83% in 2025.
  • Over 5 years, Cash & Equivalents stood at $77.9 million in 2021, then increased by 17.22% to $91.3 million in 2022, then dropped by 16.88% to $75.9 million in 2023, then decreased by 3.91% to $72.9 million in 2024, then skyrocketed by 41.83% to $103.4 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $103.4 million, $72.9 million, and $75.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.